Company: RVRC
Filing Date: 2025-08-13
Form Type: S-1/A
Source: 0001213900-25-075747
Chunk: 73

Company: Revium Rx.
Filing Date: 2025-08-13
Form: S-1/A
Chunk 73
---
 offerings, we will have sufficient cash resources
to fund our operations and business plan at least through the next twelve months. Our ongoing operations through the conduct of the clinical
trial program will continue to consume cash resources without generating revenues. There is no guarantee that will be successful in obtaining
an adequate level of financing needed for its long-term research and development activities on commercially reasonable terms.

Foreign Exchange Risks

Our financial statements
are denominated in U.S. dollars and financial results are denominated in U.S. dollars, while a significant portion of our business is
conducted, and a substantial portion of our operating expenses are payable, in currencies other than the U.S. dollar.

Exchange rate fluctuations
may have an adverse impact on our future revenues, if any, or expenses as presented in the financial statements. We may in the future
use financial instruments, such as forward foreign currency contracts, in its management of foreign currency exposure. These contracts
would primarily require us to purchase and sell certain foreign currencies with or for U.S. dollars at contracted rates. We may be exposed
to a credit loss in the event of non-performance by the counterparties of these contracts. In addition, these financial instruments may
not adequately manage our foreign currency exposure. Our results of operations could be adversely affected if we are unable to successfully
manage currency fluctuations in the future.

Effects of Inflation

Inflation generally
affects Revium by increasing its research and development expenses. Revium does not believe that inflation and changing prices had a
significant impact on its results of operations for any periods presented herein, but may have a significant, adverse impact in 2025.

<div align='center'>43

DESCRIPTION OF BUSINESS

Overview</div>

We are a pre-clinical stage biopharmaceutical company focused on the development and eventual commercialization of innovative and proprietary nanoparticle-based
therapies. We focus on creating smarter, more targeted treatments that improve how medicines work in the body, with the goal of increasing effectiveness while reducing side effects.We are developing advanced lipid-based platforms
for a variety of potential uses, including areas with high unmet-needs such as antimicrobial resistance and solid tumors.

Our work is inspired by Professor Yehezkel
Barenholz, a world leader in this field and one of the original innovators behind liposomal drug delivery. His decades of research have
shaped some of today’s most important cancer treatments. At Revium Rx, we’re taking this legacy further, using our technology
to